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Background: Arsenic trioxide (ATO) is reported to be an effective therapeutic agent in acute promyelocytic leukemia
(APL) through inducing apoptotic cell death. Buthionine sulfoximine (BSO), an oxidative stress pathway modulator, is
suggested as a potential combination therapy for ATO-insensitive leukemia. However, the precise mechanism of BSO-
mediated augmentation of ATO-induced apoptosis is not fully understood. In this study we compared the difference in
cell death of HL60 leukemia cells treated with ATO/BSO and ATO alone, and investigated the detailed molecular
mechanism of BSO-mediated augmentation of ATO-induced cell death.
Methods: HL60 APL cells were used for the study. The activation and expression of a series of signal molecules were
analyzed with immunoprecipitation and immunoblotting. Apoptotic cell death was detected with caspases and poly
(ADP-ribose) polymerase activation. Generation of intracellular reactive oxygen species (ROS) was determined using a
redox-sensitive dye. Mitochondrial outer membrane permeabilization was observed with a confocal microscopy
using NIR dye and cytochrome c release was determined with immunoblotting. Small interfering (si) RNA was
used for inhibition of gene expression.
Results: HL60 cells became more susceptible to ATO in the presence of BSO. ATO/BSO-induced mitochondrial
injury was accompanied by reduced mitochondrial outer membrane permeabilization, cytochrome c release and
caspase activation. ATO/BSO-induced mitochondrial injury was inhibited by antioxidants. Addition of BSO induced
phosphorylation of the pro-apoptotic BCL2 protein, BIMEL, and anti-apoptotic BCL2 protein, MCL1, in treated cells.
Phosphorylated BIMEL was dissociated from MCL1 and interacted with BAX, followed by conformational change
of BAX. Furthermore, the knockdown of BIMEL with small interfering RNA inhibited the augmentation of ATO-
induced apoptosis by BSO.
Conclusions: The enhancing effect of BSO on ATO-induced cell death was characterized at the molecular level
for clinical use. Addition of BSO induced mitochondrial injury-mediated apoptosis via the phosphorylation of
BIMEL and MCL1, resulting in their dissociation and increased the interaction between BIMEL and BAX.
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Arsenic trioxide (ATO) has been reported to be an ef-
fective therapeutic agent in both newly diagnosed and
relapsed patients with acute promyelocytic leukemia
(APL) [1,2]. This success has prompted an interest in
understanding the molecular mechanisms of action
underlying the clinical effectiveness of ATO. ATO is re-
ported to induce apoptosis in leukemic promyelocytes
[3,4]. ATO-induced apoptosis appears to be dependent
on the intracellular redox homeostasis. In particular, the
effectiveness of ATO in inducing to apoptosis is associ-
ated with an increased generation of intracellular react-
ive oxygen species (ROS) [5,6]. However, the antitumor
effect of ATO is limited in other types of leukemia and
solid tumor cells, since these cancer cell types have low
susceptibility to ATO [7,8]. Previous studies suggest that
the ineffectiveness of ATO in ATO-resistant tumors may
be due to low ROS levels, preventing the triggering of
effective apoptosis [5,9,10]. These early studies thus pro-
vide a rationale for utilizing ATO in combination with
oxidative pathway modulators to extend the use of ATO
for treating non-APL malignacies. Buthionine sulfoxi-
mine (BSO), which is known to effectively deplete cellu-
lar glutathione [11], is used to augment ATO-induced
apoptosis [12-14]. However, the precise mechanism of
BSO-mediated augmentation of ATO-induced apoptosis
remains unclear. In particular, the molecular events in
mitochondria involved in increased apoptotic suscepti-
bility are unknown. In this study we investigated the de-
tailed molecular mechanism of mitochondrial injury-
mediated cell death by treating HL60 with ATO/BSO,
compared with that with ATO alone. We report that the
dissociation of BIMEL and MCL1 and the subsequent
interaction of BIMEL and BAX play a critical role in
BSO-mediated augmentation of ATO-induced apoptosis.
Methods
Reagents
ATO, BSO, n-acetylcysteine (NAC), dithiothreitol (DTT),
SP600125, U0126, PD035901 and SB203580 were pur-
chased from Sigma Chemical (St. Louis, MO, USA). The
following antibodies were obtained from Cell Signaling
Technology (Beverly, MA, USA): antibodies to the cleaved
form of caspase 3 (C-cas3), caspase 9 (C-cas9), poly (ADP-
ribose) polymerase (C-PARP); antibodies to normal and
phosphorylated forms of MCL1 (MCL1, P-MCL1 at
Ser159/Thr163), BCL2 (BCL2, P-BCL2 at Ser70), BIM
(BIM, P-BIM at Ser69), JNK (JNK, P-JNK at Thr183/
Tyr185), c-JUN (c-JUN, P-c-JUN at Ser63), p38 (p38, P-p38
at Thr180/Tyr182) and ERK1/2 (ERK1/2, P-ERK1/2 at
Thr202/Tyr204); antibodies to actin, BAD, BID and BOK.
Antibodies to BAK, ASK, and normal and phosphorylated
forms of BCLxL (BCLxL, P-BCLxL at Ser62) were obtained
from Abcam (Cambridge, MA, USA). Antibodies to mouseand human phosphorylated forms of ASK1 (P-ASK1 at
Thr845 or at Thr838) [15] was provided by Dr. H. Ichijo,
the University of Tokyo.Cell culture
The HL60 cell line, which was derived from peripheral
blood cells of a 36-year old Caucasian female with APL,
was obtained from ATCC (Manassas, VA, USA). Cells
were maintained in RPMI-1640 medium supplemented
with 10% heat inactivated fetal bovine serum.Cell viability
Cell viability was determined using a cell proliferation kit
(XTT) (Roche Applied Sciences, Rotkreuz, Switzerland) as
described elsewhere [16]. The half-maximal inhibitory con-
centration (IC50) was calculated using Graphpad PRISM
software (GraphPad, San Diego, CA, USA). The nontoxic
concentrations of various reagents were confirmed by the
XTT test.Identification of apoptotic cell death
Apoptotic cells were identified using a cell death detec-
tion kit (Roche Applied Sciences) using mouse monoclo-
nal antibodies against fragmented DNA and histones
according to the manufacturer’s instructions.Determination of intracellular ROS level
The generation of intracellular ROS was determined
using a redox-sensitive dye 5-(and-6)-chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate probe (CM-H2DCFDA)
(Molecular probes, Eugene, Oregon, USA) according to the
manufacturer’s instructions.Determination of mitochondrial outer membrane
permeability (MOMP)
Cells were incubated with NIR dye supplied in a NIR
mitochondrial membrane potential assay kit (Abcam) and
1 μM Hoechst 33342 dye for 30 min at 37˚C. Stained cells
were subjected to confocal microscopy (Leica TCS SP II,
Wetzlar, Germany). The fluorescence ratio of the two dyes
was determined for quantitative analysis of MOMP. The
Leica confocal software, a MetaMorph ver.7.8 (Molecular
Devices) was used for the analysis.Determination of cytochrome c release
The release of cytochrome c was determined using an
ApoAlert cell fractionation kit (Clontech, Mountain View,
USA). The cells were processed according to the manufac-
turer’s instructions and the concentration of released cyto-
chrome c in the cytosolic fractions was determined by














































Figure 1 BSO augments ATO-induced cell death via intracellular ROS generation. A, HL60 cells were treated with ATO (3 μM) or ATO/BSO
(3 μM/50 μM) in the presence or absence of NAC (5 mM) or DTT (0.6 mM) for 12 h. Cell viability was determined using a XTT assay. *p < 0.05,
Treatment with ATO in the presence of NAC or DTT treatment vs. treatment with ATO in the absence of NAC and DTT; **p < 0.01, Treatment with
ATO/BSO in the presence of NAC or DTT treatment vs. treatment with ATO/BSO in the absence of NAC and DTT. B, Cells were treated with ATO
or ATO/BSO for 6 h. The levels of intracellular ROS were monitored. *p < 0.05, Treatment with ATO vs. treatment with none; **p < 0.01, Treatment
with ATO/BSO vs. treatment with none.
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Cells were lysed in CHAPS buffer (10 mM Hepes,
pH7.5, 150 mM NaCl, 2% CHAPS) or RIPA buffer
(50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate, 1.0% NP-40)
containing protease inhibitor cocktail (Nacalai Tesque,
Kyoto, Japan) and phosphatase inhibitor cocktail I
(Wako Pure Chemical, Osaka, Japan). Protein lysates
(500 μg of protein) in CHAPS buffer were subjected to
immunoprecipitation using an antibody to BAX 6A7
(BD Biosciences, San Jose, CA, USA), BAK Ab1
(Abcam), BIM (Cell Signaling Technology) or MCL1
(BD Pharmingen). The immunoprecipitates or whole cell
lysates (10 μg of protein) were analyzed by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis on 7.5-15%























































Figure 2 BSO augments ATO-induced cell death via ROS-mediated m
cytochrome c and the cleavage of caspase 9 were determined by immunoblot
confocal microscopy. Magnification ×40. The results are presented as % untreat(BIO-RAD, Hercules, CA, USA). Immunoblots were
treated with primary and secondary antibodies and then
analyzed using an ECL-Advance Western blotting kit
(GE Healthcare, Little Chalfont, England). In several ex-
periments, band intensities were quantified using a
LAS4000 imaging system (GE Healthcare).Transfection with small interfering (si) RNA
HL60 cells (1 × 106 cells) were transfected with two distinct
siRNA (BIM#1 and BIM#2) specifically designed against
human BIMEL, or with a control non-silencing siRNA
(Silencer Select; Life Technologies, Carlsbad, CA, USA)
using hemagglutinating virus supplied in a Japan-envelope
vector kit (GenomONE-Si; Ishihara Sangyo, Osaka, Japan),
according to the manufacturer’s instructions. The cells were Dye MergeHoechst
Relative MOMP level 





itochondrial injury. A, After treatment as Figure 1A, the release of
ting. B, MOMP with NIR dye and Hoechst staining was analyzed by



























































































Figure 3 BSO induces conformational change in BAX, but not BAK.
The conformational change was detected using immunoprecipitation
and immunoblotting with an antibody to conformationally changed
BAX or BAK. HL60 cells were treated with ATO/BSO or ATO for 12 h in
the presence or absence of DTT. Actin and IgG light chain (IgG(L)) were
used as the controls. A typical result of 3 independent experiments is











































































































Figure 4 BSO induces phosphorylation of BIMEL and MCL1 in mitocho
or absence of NAC or DTT for 12 h. A. The expression and phosphorylation
indicates a longer exposure of the same blot. B, C. The expression and pho
determined by immunoblotting.
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siRNA.
Statistical analysis
Experimental values are represented as the mean ±
standard deviation in triplicate. The experiments were
carried out at least 3 times. The significance of differ-
ence between experimental and control groups was de-
termined by the Student’s t-test. A value of p < 0.05 was
considered statistically significant.
Results
BSO augments ATO-induced cell death via intracellular
ROS generation
The effect of BSO on ATO-induced cell death using
HL60 cells was examined by determining cell viability
(Figure 1A). BSO significantly augmented ATO-induced
cell death. Approximately 80% of HL60 cells died when
exposed to ATO in the presence of BSO, whereas ATO
alone killed approximately 30% of the cells (p < 0.01,
ATO alone or ATO/BSO vs. none). Since ATO-induced
cell death is associated with generation of intracellular
ROS [5,6], the effect of the antioxidants, NAC and DTT,


































































































ndria. HL60 cells were treated with ATO/BSO or ATO in the presence
of BIM were determined by immunoblotting. The lower panel
sphorylation of BAD, BID, tBID, MCL1, BCLxL and BCL2 were
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cell death, suggesting that ROS play an important role in
BSO-mediated augmentation of ATO-induced cell death.
To confirm the ROS generation directly in ATO/BSO-
treated cells, intracellular ROS generation was determined
using a fluorescent probe, CM-H2DCFDA dye (Figure 1B).
ATO/BSO treatment markedly increased the ROS gener-
ation, although ATO alone treatment did it only slightly.BSO augments ATO-induced cell death via ROS-mediated
mitochondrial injury
In the preceding section, BSO augmented ATO-induced
cell death via intracellular ROS generation. To clarify in-
volvement of ROS-mediated mitochondrial injury in
BSO-mediated augmentation, the effect of BSO on the
release of cytochrome c, a marker of mitochondrial in-
jury, in ATO-treated cells was examined by immuno-
blotting. BSO significantly augmented ATO-induced
cytochrome c release whereas ATO alone induced slight
release of cytochrome c (Figure 2A). The cytochrome c
release was abolished by antioxidants (Figure 2A). Fur-
ther, BSO markedly augmented the activation of caspase1.0   2.0 1.4 1.6         1.0   0.4  0.7 1.5            1.0  
































































Figure 5 BSO induces the dissociation of phosphorylated BIMEL from
phosphorylated BIMEL and MCL1, and the interaction with BAX were determ
their normal and phosphorylated forms. Values were normalized to actin o
control. A typical result of 3 independent experiments is shown. IP, immun9, which is triggered by released cytochrome c and is in-
volved in an early stage of mitochondrial apoptosis. On
the other hand, the caspase 9 activation was hardly de-
tected in ATO alone treatment. To confirm BSO-
mediated mitochondrial injury, the effect of ATO/BSO
treatment on MOMP was examined with a confocal
microscope. Addition of BSO significantly reduced NIR
stain in ATO-treated cells whereas ATO did it only min-
imally (Figure 2B). Thus, BSO was suggested to augment
ATO-induced cell death via mitochondrial injury charac-
terized by cytochrome c release, caspase 9 activation and
MOMP reduction.BSO induces conformational change in BAX, but not
in BAK
Since the two proapoptotic BCL2 effector proteins, BAX
and BAK, play central roles in oxidative stress-mediated
mitochondrial apoptosis [17,18], the effect of BSO
addition on the conformational change of BAX and BAK
in ATO-treated cells was examined by immunoprecipita-
tion and immunoblotting. Immunoblotting analysis with
anti-whole BAX antibody demonstrated no significantIP:   MCL1
SupPpt
1.9 1.4  1.1        1.0  1.9 1.1  1.2
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MCL1 and the interaction with BAX. A and B, The dissociation of
ined by immunoprecipitation and immunoblotting with antibodies to
r IgG(L), respectively and represent relative changes compared with
oprecipitation; Ppt, immunoprecipitate; Sup, supernatant.
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and ATO alone treatment. However, an antibody which
defines conformationally changed BAX immunoprecipi-
tated much more BAX in ATO/BSO-treated cells than
ATO alone-treated cells (Figure 3, upper panel). An
anti-whole BAX antibody immunoprecipitated a lower
level of BAX from the supernatant fraction of ATO/
BSO-treated cells. Therefore, BSO was suggested to trig-
ger conformational change of BAX in ATO/BSO treat-
ment. In addition, the conformational change of BAX in
ATO/BSO-treated cells was prevented by DTT as an
antioxidant (Figure 3, upper panel).
Immunoprecipitation analysis using an antibody to
whole BAK or conformationally changed BAK demon-
strated no presence of conformationally changed BAK in
either ATO/BSO or ATO alone treatment (Figure 3,
lower panel).ATO/BSO
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Figure 6 Silencing of BIMEL with si RNA abolishes ATO/BSO-
induced cell death. The expression of BIMEL and cleavage of caspase
3 and PARP were determined by immunoblotting. HL60 cells were
transfected with two siRNAs designed against BIMEL (BIM#1 and BIM#2)
or control siRNA, incubated for 48 h, and treated with ATO/BSO for
12 h. A typical result of 3 independent experiments is shown. IP,
immunoprecipitation; Ppt, immunoprecipitate.BSO induces phosphorylation of BIMEL and MCL1 in
mitochondria
A possibility was raised that the conformational change
of BAX might be critical for BSO-mediated mitochon-
drial injury. Therefore, we examined the expression and
activation of a series of BCL2-family proteins, which
affect the conformational change of BAX [19,20]. First,
the expression of BIMEL, a proapoptotic protein in the
BCL2 family, was analyzed by immunoblotting. Normal
HL60 cells expressed a readily detectable level of the
two major BIM isoforms, BIMEL and BIML whereas
they expressed a low level of the smallest isoform, BIMS
(Figure 4A upper panel). BIMEL (23 kDa) underwent an
electrophoretic mobility shift (24–26 kDa) following ATO/
BSO treatment whereas the smaller isoform, BIML did not.
BSO addition caused a high level of S69-phosphorylated
BIMEL (Figure 4A). The enhanced BIMEL phosphorylation
was abolished by NAC or DTTas antioxidants (Figure 4A).
In contrast, neither mobility shift nor phosphorylation of
BIMEL was induced by ATO alone. There was no signifi-
cant difference in the expression of the other pro-apoptotic
proteins of the BCL2 family, BAD and BID between ATO/
BSO and ATO treatment (Figure 4B).
Second, the effect of BSO addition on the expression
and activation of MCL1, an anti-apoptotic protein of the
BCL2 family, was examined. BSO addition augmented
the expression and phosphorylation of MCL1 at Ser159
and/or Thr163, whereas ATO alone did it only minimally
(Figure 4C). The BSO-mediated augmentation of MCL1
expression and phosphorylation was abolished by antiox-
idants. Similar augmentation was seen in phosphoryl-
ation of BCLXL (Figure 4C). In addition, there was no
significant difference in the BCL2 expression in ATO/
BSO treatment in the presence or absence of antioxi-
dants (Figure 4C).BSO induces the dissociation of phosphorylated BIMEL
from MCL1
Since MCL1 is a preferred binding partner for BIM [21],
and BIM phosphorylation is known to influence the
binding to prosurvival BCL2-family proteins, especially
MCL1 [22,23], the phosphorylation of BIMEL and/or
MCL1 disrupting the complex formation between BIMEL
and MCL1 was examined using immunoprecipitation
and immunoblotting. The MCL1-BIMEL complex was
detected in untreated control cells (Figure 5A, MCL1
lane 5). BSO augmented the phosphorylation of BIMEL
(Figure 5A, P-BIMEL lane 2) and the expression of
MCL1 (Figure 5A, MCL1 lane 2), but reduced the level
of MCL1 that co-precipitated with BIMEL (Figure 5A,
MCL1 lane 6). The reduced interaction between BIMEL
and MCL1 was also confirmed using an MCL1-specific
antibody (Figure 5A, BIMEL lane 14). Furthermore, the
interaction between MCL1 and phosphorylated BIMEL was
low (Figure 5A, P-BIMEL lane 14). In contrast, ATO alone
did not induce the phosphorylation of BIMEL (Figure 5A,
P-BIMEL lane 3) but rather slightly reduced the amount of
MCL1 that co-precipitated with BIMEL (Figure 5A, MCL1
lane 7).
BSO induces the interaction of phosphorylated BIMEL
with BAX
Since BIM promotes apoptosis through binding directly
to BAX and inducing conformational changes [24,25],
the interaction between BIMEL dissociated from MCL1
and BAX in ATO/BSO treatment was examined using
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duced the amount of non-phosphorylated (basal) BIMEL
and increased the amount of BIMEL slower migrating
forms (phosphorylated BIMEL) in cell lysate (Figure 5B,
left panel). The BIMEL slower migrating form was de-
tected in immunoprecipitates of BAX in ATO/BSO-
treated cells but few in ATO alone-treated cells (Figure 5B,
right panel). To confirm the interaction between BAX and
phosphorylated BIMEL, BAX immunoprecipitates were
analyzed by immunoblotting with an anti-phosphorylated
BIMEL antibody (Figure 5B, right panel). Phosphorylated
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Figure 7 BSO triggers phosphorylation of MCL1and BIMEL via activati
determined by immunoblotting. HL60 cells were treated with ATO/BSO or
phosphorylation of BIMEL and MCL1, and the cleavage of caspase 3 and PA
ATO/BSO or ATO in the presence of SP600125 (10 μM) as a JNK inhibitor, U
inhibitor, PD035901 (100 nM)as a MEK1/2 inhibitor for 12 h. A typical resultin ATO-treated cells. BSO was suggested to augment the
interaction between phosphorylated BIMEL and BAX.
Silencing of BIMEL with si RNA abolishes ATO/BSO-induced
cell death
To confirm the importance of BIMEL in BSO-mediated
augmentation of ATO-induced cell death, the effect of
gene silencing of BIMEL on ATO/BSO-induced cell death
was examined (Figure 6). Transfection of HL60 cells with
BIMEL-specific siRNA significantly decreased the expres-
sion level of BIMEL whereas the negative control siRNA
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on of JNK. A, The phosphorylation of JNK, ERK1/2 and p38 was
ATO in the presence or absence of NAC or DTT for 12 h. B, The
RP, were determined by immunoblotting. HL60 cells were treated with
0126 (2 μM) as an ERK1/2 inhibitor, or SB203580 (10 μM) as a p38
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apoptosis, in ATO/BSO-treated cells, suggesting the critical
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+ -NQDI1BSO triggers phosphorylation of MCL1 and BIMEL via
activation of JNK
To determine which mitogen-activated protein kinases
(MAPKs) trigger phosphorylation of BIMEL and MCL1
in response to ATO/BSO, the effect of BSO addition on
ATO-induced activation of JNK, ERK1/2 and p38 was
examined. As shown in Figure 7A, BSO augmented
phosphorylation of JNK, ERK1/2 and p38 in ATO-
treated cells. The phosphorylation of these proteins was
largely abolished by the presence of antioxidants. Fur-
thermore, the effect of a series of pharmacological inhib-
itors against MAPKs on BSO-induced phosphorylation
of BIMEL and MCL1 was examined (Figure 7B).
SP600125, a JNK inhibitor, inhibited phosphorylation of
MCL1 and BIMEL (Figure 7B, left panel) whereas a p38
inhibitor (SB203580) augmented phosphorylation of
BIMEL and MCL1 compared to the untreated control
(Figure 7B, right panel). An ERK1/2 inhibitor (U0126)
did not affect the phosphorylation of BIMEL and MCL1
(Figure 7B, middle panel). The phosphorylation of
BIMEL and MCL1 corresponded to the activation of cas-
pase 3 and PARP (Figure 7B, upper panel). Further, the ef-
fect of a MEK1/2 inhibitor, PD035901, in combination
with SP600125 or U0126 was examined (Figure 7B, lower
panel). A combination of PD035901 and SP600125 com-
pletely blocked BSO-induced phosphorylation of BIMEL
present as slower migrating forms. A combination of
PD035901 and U0126 did not affect BIMEL S
69 phosphor-
ylation but blocked slower migrating forms. The phosphor-
ylation of BIMEL corresponded to the activation of PARP.Figure 8 BSO triggers activation of ASK1 and JNK and induces
phosphorylation of BIMEL and MCL1. A, The phosphorylation of
ASK1 was determined by immunoblotting. HL60 cells were treated
with ATO/BSO or ATO in the presence or absence of NAC or DTT for
12 h. B, The phosphorylation of JNK, BIMEL, and MCL1, and cleavage
of caspase 3 and PARP, were determined by immunoblotting. HL60
cells were treated with ATO/BSO or ATO in the presence or absence
of NQDI1 (10 μM) for 12 h. A typical result of 3 independent
experiments is shown.BSO triggers activation of ASK1 and JNK and induces
phosphorylation of BIMEL and MCL1
ASK1 is activated by ATO through ROS accumulation
[26] and induces activation of JNK and p38 [27]. To
confirm the involvement of ASK1 in BSO-mediated aug-
mentation of ATO-induced cell death, the effect of BSO
addition on the activation of ASK1 in ATO-treated cells
was examined. Thr838 of ASK1 was markedly phosphory-
lated by BSO addition whereas no obvious phosphoryl-
ation was observed upon ATO alone (Figure 8A). The
phosphorylation was inhibited by antioxidants (Figure 8A).
Furthermore, the effect of an ASK1 inhibitor, NQDI1 [28],
on the phosphorylation of JNK, MCL1 and BIMEL was ex-
amined (Figure 8B). NQDI1 inhibited BSO-mediated
phosphorylation of JNK, MCL1 and BIMEL and the cleav-
age of caspase 3 and PARP (Figure 8B). BSO was sug-
gested to activate ASK1 and induce the activation of
MCL1, BIMEL, caspase 3 and PARP.Discussion
In the present study, we have demonstrated that BSO
augments ATO-induced cell death in HL60 cells and
that the augmentation is responsible for ROS-mediated
mitochondrial apoptosis. The detailed molecular mech-
anism of BSO-mediated mitochondrial injury was stud-
ied by comparing ATO cell death in the presence or
absence of BSO. We here report that BSO augments
intracellular ROS production in mitochondria and
induces a series of molecular events, such as
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dissociation of BIMEL and MCL1, and interaction of
BIMEL and BAX.
Previously several groups showed that BSO decreased
the levels of glutathione and enhanced ATO-induced
apoptosis [29,30]. Chen et al. reported that ATO/BSO
induced apoptosis in ATO-sensitive and insensitive
leukemia cells through activation of JNK, which up-
regulated death receptor (DR) 5 and the caspase 8 path-
way [30]. However, they did not report the accumulation
of ROS in ATO/BSO-induced apoptosis, nor the associ-
ated molecular events occurring in mitochondria. We
have demonstrated that ATO/BSO induces the dissoci-
ation of BIMEL from MCL1, and that its interaction with
BAX plays a critical role in ATO/BSO-induced apoptosis
via conformational changes in BAX. Our results demon-
strate that BSO causes ROS-mediated mitochondrial in-
jury, accompanied by cytochrome c release and reduced
MOMP. This is the first report showing the involvement
of ROS-mediated mitochondrial injury in BSO-mediated
augmentation of ATO-induced apoptosis. Moreover, we
show the pivotal role played by the pro-apoptotic mol-
ecule, BIMEL, in ATO/BSO-induced apoptosis, and con-
firm it by the finding that knockdown of BIMEL
abolishes ATO/BSO-induced apoptosis. The remarkable
behavior of pro-apoptotic BIMEL in mitochondria pro-









Figure 9 The putative molecular events occurring in mitochondria duATO/BSO-induced apoptosis. Pro-apototic effects are
reported to be associated with BIML activation [31].
However, we could not confirm the activation of BIML
in this study. Rather, the role of BIMEL might be more
important than that of BIML, although we do not ex-
clude the involvement of BIML in ATO/BSO-induced
apoptosis.
BSO induces phosphorylation of BIMEL and MCL1 in
ATO-treated cells. Phosphorylated BIMEL is dissociated
from MCL1 and interacts with BAX. The complex for-
mation between phosphorylated BIMEL and BAX trig-
gers a conformational change in BAX, leading to the
dysfunction of MOMP and the release of cytochrome c.
Finally, ATO/BSO-treated cells undergo apoptosis via
activation of cytochrome c-mediated caspase 9, caspase
3 and PARP. The putative molecular events occurring in
mitochondria for BSO-mediated augmentation of ATO-
induced apoptosis are summarized in Figure 9. There
are several reports on the phosphorylation and dissoci-
ation of BIM and MCL1 [23,32,33]. The withdrawal of
serum survival factors is reported to induce the phos-
phorylation of BIM at Ser65 (Ser69 in human) and dis-
sociation from MCL1 and BCLxL [32]. In normal B cells
treated with anti-IgM antibody, the phosphorylation of
BIM at Ser69 has been reported to play a regulatory role
in the release of MCL1 [33]. However, these studies re-
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sults demonstrate that the dissociation of BIMEL from
MCL1 leads to cell death in ATO/BSO-treated cells. The
crucial role of BIMEL phosphorylation in apoptosis has
been reported previously for cell death induced by
trophic factor deprivation [34] and diallyl trisulfide [35],
although the dissociation of BIMEL and MCL1 was not
observed. There remained a possibility that phosphatase
inhibition might be involved in the phosphorylation of a
series of signal molecules.
The critical role of ASK1 in apoptosis induction has
been reported [36-38]. We have found that BSO triggers
activation of ASK1 in ATO-treated cells. The involve-
ment of ASK1 activation in ATO/BSO-induced apop-
tosis is confirmed by using pharmacological inhibitors,
although it must be confirmed by more specific tech-
nique. Yan et al. [26] reported that ASK1 is activated by
ATO through ROS accumulation, and that it negatively
regulates apoptosis in leukemia cells without activating
JNK and p38. In contrast, our results clearly show that
ASK1 activated by BSO causes the activation of JNK and
p38. The difference between the two studies might be
due to excessive ROS generation in response to ATO/
BSO. ASK1 is a member of the MAPK kinase kinase
family and activates JNK and p38 MAPKs in response to
an array of stresses such as oxidative stress, endoplasmic
reticulum stress and calcium influx [27]. It is reasonable
that BSO activates ASK1 via oxidative stress and then
activates JNK and p38. Inhibition of p38 with a pharma-
cological inhibitor induces the activation of caspase 3
and PARP in ATO/BSO-induced apoptosis, suggesting
negative feedback of p38 against ATO/BSO-induced
apoptosis. The precise role of ASK1 and MAPKs in
ATO/BSO-mediated apoptosis must await further
characterization.Conclusions
ATO/BSO combined treatment induces ROS-mediated
mitochondrial apoptosis in HL60 cells. ATO/BSO-induced
mitochondrial apoptosis is caused by successive BIMEL al-
terations consisting of phosphorylation, dissociation from
MCL1, and interaction with BAX. The enhancing effect of
BSO on ATO-induced apoptosis was characterized at the
molecular level for clinical use.
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